EVOK
Price
$2.34
Change
-$0.25 (-9.65%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
5.17M
SIGA
Price
$5.21
Change
-$0.29 (-5.27%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
608.54M
28 days until earnings call
Ad is loading...

EVOK vs SIGA

Header iconEVOK vs SIGA Comparison
Open Charts EVOK vs SIGABanner chart's image
Evoke Pharma
Price$2.34
Change-$0.25 (-9.65%)
Volume$200
Capitalization5.17M
SIGA Technologies
Price$5.21
Change-$0.29 (-5.27%)
Volume$6.82K
Capitalization608.54M
EVOK vs SIGA Comparison Chart
Loading...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SIGA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVOK vs. SIGA commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVOK is a Hold and SIGA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (EVOK: $2.59 vs. SIGA: $5.50)
Brand notoriety: EVOK and SIGA are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EVOK: 190% vs. SIGA: 79%
Market capitalization -- EVOK: $5.17M vs. SIGA: $608.54M
EVOK [@Pharmaceuticals: Other] is valued at $5.17M. SIGA’s [@Pharmaceuticals: Other] market capitalization is $608.54M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVOK’s FA Score shows that 0 FA rating(s) are green whileSIGA’s FA Score has 2 green FA rating(s).

  • EVOK’s FA Score: 0 green, 5 red.
  • SIGA’s FA Score: 2 green, 3 red.
According to our system of comparison, SIGA is a better buy in the long-term than EVOK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVOK’s TA Score shows that 3 TA indicator(s) are bullish while SIGA’s TA Score has 3 bullish TA indicator(s).

  • EVOK’s TA Score: 3 bullish, 5 bearish.
  • SIGA’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, EVOK is a better buy in the short-term than SIGA.

Price Growth

EVOK (@Pharmaceuticals: Other) experienced а -10.07% price change this week, while SIGA (@Pharmaceuticals: Other) price change was -4.01% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -3.00%. For the same industry, the average monthly price growth was +65.26%, and the average quarterly price growth was -10.39%.

Reported Earning Dates

EVOK is expected to report earnings on Nov 08, 2024.

SIGA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-3.00% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SIGA($609M) has a higher market cap than EVOK($5.17M). SIGA YTD gains are higher at: -8.486 vs. EVOK (-41.403). SIGA has higher annual earnings (EBITDA): 84.2M vs. EVOK (-7.29M). SIGA has more cash in the bank: 150M vs. EVOK (4.74M). SIGA has less debt than EVOK: SIGA (564K) vs EVOK (5M). SIGA has higher revenues than EVOK: SIGA (140M) vs EVOK (5.18M).
EVOKSIGAEVOK / SIGA
Capitalization5.17M609M1%
EBITDA-7.29M84.2M-9%
Gain YTD-41.403-8.486488%
P/E RatioN/A9.24-
Revenue5.18M140M4%
Total Cash4.74M150M3%
Total Debt5M564K887%
FUNDAMENTALS RATINGS
EVOK vs SIGA: Fundamental Ratings
EVOK
SIGA
OUTLOOK RATING
1..100
174
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
1
Undervalued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
10033
PRICE GROWTH RATING
1..100
9676
P/E GROWTH RATING
1..100
7686
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SIGA's Valuation (1) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVOK (40). This means that SIGA’s stock grew somewhat faster than EVOK’s over the last 12 months.

SIGA's Profit vs Risk Rating (89) in the Pharmaceuticals Other industry is in the same range as EVOK (100). This means that SIGA’s stock grew similarly to EVOK’s over the last 12 months.

SIGA's SMR Rating (33) in the Pharmaceuticals Other industry is significantly better than the same rating for EVOK (100). This means that SIGA’s stock grew significantly faster than EVOK’s over the last 12 months.

SIGA's Price Growth Rating (76) in the Pharmaceuticals Other industry is in the same range as EVOK (96). This means that SIGA’s stock grew similarly to EVOK’s over the last 12 months.

EVOK's P/E Growth Rating (76) in the Pharmaceuticals Other industry is in the same range as SIGA (86). This means that EVOK’s stock grew similarly to SIGA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOKSIGA
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
N/A
Bullish Trend 17 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SIGA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AIXI4.230.22
+5.49%
XIAO-I Corporation
ADIL0.690.03
+5.18%
Adial Pharmaceuticals
ACM95.841.98
+2.11%
Aecom
CCAP17.06-0.07
-0.41%
Crescent Capital BDC
CWT48.50-0.21
-0.43%
California Water Service

EVOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVOK has been loosely correlated with RDHL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if EVOK jumps, then RDHL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVOK
1D Price
Change %
EVOK100%
-5.82%
RDHL - EVOK
33%
Loosely correlated
-3.92%
NBIX - EVOK
28%
Poorly correlated
+1.22%
EOLS - EVOK
26%
Poorly correlated
+1.92%
SIGA - EVOK
25%
Poorly correlated
+0.36%
PRFX - EVOK
25%
Poorly correlated
+2.68%
More